Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial

Circulation

Volumn 114, Issue 25, 2006, Pages 2766-2772

  Saxon, Leslie A ^a,k   Bristow, Michael R ^b   Boehmer, John ^c   Krueger, Steven ^d   Kass, David A ^e   Marco, Teresa De ^f   Carson, Peter ^g   DiCarlo, Lorenzo ^h   Feldman, Arthur M ⁱ   Galle, Elizabeth ^j   Ecklund, Fred ^j  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d Bryan LGH Medical Center   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h PFIZER INC   (United States)

ⁱ THOMAS JEFFERSON UNIVERSITY   (United States)

^j BOSTON SCIENTIFIC CORPORATION   (United States)

^k USC UNIVERSITY HOSPITAL   (United States)

more..

Author keywords

Arrhythmia; Death, sudden; Defibrillation; Electrophysiology; Heart failure; Implantable cardioverter defibrillators

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HORMONE ANTAGONIST; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEFIBRILLATION; DEFIBRILLATOR; DISEASE SEVERITY; FEMALE; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PACING; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QRS COMPLEX; RISK ASSESSMENT; RISK REDUCTION; SHOCK; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; CARDIAC PACING, ARTIFICIAL; DEATH, SUDDEN, CARDIAC; ELECTRIC COUNTERSHOCK; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; RISK ASSESSMENT; SHOCK, CARDIOGENIC; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33845895730     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.642892     Document Type: Article

References (24)

1. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-2150.
2. Carson P, Anand I, O'Connor C, Jaski B, Steinberg J, Lwin A, Lindenfeld J, Ghali J, Barnet JH, Feldman AM, Bristow MR. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol. 2005;46:2329-2334.
3. Wilber DJ, Zareba W, Hall WJ, Brown MW, Lin AC, Andrews ML, Burke M, Moss AJ. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation. 2004;109:1082-1084.
4. Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW, Daubert JP, McNitt S, Andrews ML, Elkin AD; Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II) Research Group. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 2004;110:3760-3765.
5. Whang W, Mittleman MA, Rich DQ, Wang PJ, Ruskin JN, Tofler GH, Muller JE, Albert CM; TOVA Investigators. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study. Circulation. 2004;109:1386-1391.
6. Wilkoff BL, Hess M, Young J, Abraham WT. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. J Cardiovasc Electrophysiol. 2004;15:1002-1009.
7. Higgins SL, Hummel JD, Niazi IK, Giudici MC, Worley SJ, Saxon LA, Boehmer JP, Higginbotham MB, De Marco T, Foster E, Yong PG. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol. 2003;42:1454-1459.
8. Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff BL, Canby RC, Schroeder JS, Liem D, Hall S, Wheelan K; for The Multicenter Insync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: The MIRACLE ICD Trial. JAMA 2003;289:2685-2694.
9. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J; MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-1853.
10. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure. N Engl J Med. 2005;352:1539-1549.
11. Cleland JG. New Results from the CARE-HF Programme. European Society of Cardiology Congress Reports. Available: www.escardio.org/knowledge/congresses/ CongressReports/clinical/2005/cleland.htm. Accessed online April 18, 2006.
12. Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998;317:1309-1312.
13. Luu M, Stevenson WG, Stevenson LW, Baron K, Walden J. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation. 1989;80:1675-1680.
14. Auricchio A, Stellbrink C, Butter C, Sack S, Vogt J, Misier AR, Bocker D, Block M, Kirkels JH, Kramer A, Huvelle E; Pacing Therapies in Congestive Heart Failure II Study Group; Guidant Heart Failure Research Group. Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. J Am Coll Cardiol. 2003;42:2109-2116.
15. Saxon LA, De Marco T, Schafer J, Chatterjee K, Kumar UN, Foster E; VIGOR Congestive Heart Failure Investigators. Effects of long-term biventricular stimulation for resynchronization on echocardiographic measures of remodeling. Circulation. 2002;105:1304-1310.
16. Sutton MG, Plappert T, Hilpisch KE, Abraham WT, Hayes DL, Chinchoy E. Sustained reverse left ventricular structural remodeling with cardiac resynchronization at one year is a function of etiology: quantitative Doppler echocardiographic evidence from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). Circulation. 2006;113:266-272.
17. Spragg DD, Leclercq C, Loghmani M, Faris OP, Tunin RS, DiSilvestre D, McVeigh ER, Tomaselli GF, Kass DA. Regional alterations in protein expression in the dyssynchronous failing heart. Circulation. 2003;108:929-932.
18. MERIT HF Study Group. Effect of Metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-2007.
19. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH; Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-2158.
20. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-237.
21. Zareba W, Moss AJ, Jackson Hall W, Wilber DJ, Ruskin JN, McNitt S, Brown M, Wang H; MADIT II Investigators. Clinical course and implantable cardioverter defibrillator therapy in postinfarction women with severe left ventricular dysfunction. J Cardiovasc Electrophysiol. 2005;16:1265-1270.
22. Jolly S, Dorian P, Alter DA. The impact of implantable cardiac defibrillators for primary prophylaxis in the community: baseline risk and clinically meaningful benefits. J Eval Clin Pract. 2006;12:190-195.
23. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112-S119.
24. Wase A, Basit A, Nazir R, Jamal A, Shah S, Khan T, Mohiuddin I, White C, Saklayen M, McCullough PA. Impact of chronic kidney disease upon survival among implantable cardioverter-defibrillator recipients. J Interv Card Electrophysiol. 2004;11:199-204.